Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: PHIP Updates Highlight Asset Prioritization

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: Competition Understated

Suzhou Ribo Life Science (瑞博生物) Pre-IPO Quick View: Scarcity of SiRNA Player

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>Suzhou Ribo Life, a China-based siRNA therapeutics company, launched its IPO to raise at least USD 206 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and provide a valuation for the company.</li>
<li>We think the risk-reward is not attractive for the deal.</li>
</ul>


Suzhou Ribo Life, a China-based siRNA therapeutics company, launched its IPO to raise at least USD 206 million via a Hong Kong listing.
In this note, we look at the deal terms and provide a valuation for the company.
We think the risk-reward is not attractive for the deal.


Suzhou Ribo Life Science

RiboLife-B (瑞博生物) IPO: 高値札